High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphoma
about
Advances in Primary Central Nervous System Lymphoma.High-dose cytarabine salvage therapy for recurrent primary CNS lymphoma.Single-agent rituximab for primary CNS lymphoma during pregnancy as a bridge to definitive managementCentral nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study.High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma.Age, gender, and racial differences in incidence and survival in primary CNS lymphoma.Advantages of dose-dense methotrexate protocol for primary central nervous system lymphoma: comparison of two different protocols at a single institution.Primary central nervous system lymphoma treated with high-dose methotrexate and rituximab: A single-institution experienceMedical treatment of recurrent meningiomas.Management of elderly patients with primary central nervous system lymphoma.Diagnosis and treatment of primary CNS lymphoma.Risk factors for intraocular involvement in patients with primary central nervous system lymphoma.Objective cerebrospinal fluid response to intraventricular rituximab in indolent CNS lymphomaDiagnosis and Management of Leukemic and Lymphomatous Meningitis.Primary B-cell CNS lymphoma clinicopathologic and treatment outcomes in 89 patients from a single tertiary care center.Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma.Current and emerging pharmacotherapies for primary CNS lymphoma.Advances in the treatment of newly diagnosed primary central nervous system lymphomas.Initial experience with bendamustine in patients with recurrent primary central nervous system lymphoma: a case report.Early relapses in patients with primary CNS lymphoma treated with methotrexate-based chemotherapy without consolidating whole brain irradiation.Immunochemotherapy using rituximab (RTX) and high-dose methotrexate (HD-MTX): an evaluation of the addition of RTX to HD-MTX in recurrent primary central nervous system lymphoma (PCNSL).Rituximab significantly improves complete response rate in patients with primary CNS lymphoma.Balancing relapses versus cognitive impairment in primary central nervous system lymphoma: a single-center experience.Phase II study of rituximab given in conjunction with standard chemotherapy in primary central nervous system lymphoma (PCNSL): a trial of the ECOG-ACRIN cancer research group (E1F05).What is the optimal dose of high-dose methotrexate in the initial treatment of primary central nervous system lymphoma?Salvage therapy with bendamustine for methotrexate refractory recurrent primary CNS lymphoma: a retrospective case series.Treatment of primary CNS lymphoma (PCNSL) following successful treatment of systemic non-Hodgkin's lymphoma (NHL): a case series.Response-adapted radiation therapy for newly diagnosed primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapyRapid infusion rituximab is well tolerated in patients with primary CNS lymphoma
P2860
Q31007237-BFB841AC-CF83-4182-B72C-3048F496E28BQ33427514-BDA63A95-CA6C-414A-9A65-F514BCB5C89EQ33774671-BC383467-1411-4C0D-9B02-7F8E89B7D001Q33824350-3E466CD6-314C-43D5-AFFE-DAD8997BB72EQ33981252-24360FC2-B545-4BE1-AF68-B64C276099F0Q35620605-B4FD7175-3AD4-42CF-ABB7-F83178894ECDQ35869493-B82FFEED-118A-49BC-9F72-4994FBE2D521Q36825376-317CB64E-5E59-45B6-BC92-7F8131B83DBFQ37939997-E11660FA-86A7-400A-9256-7E3680233BC3Q38096927-AAF3679A-C68E-411D-99FB-01721121B4E3Q38106613-E6E9BEB7-A79E-47D4-9808-F5B04A9D3EAAQ38239533-577E15E1-749E-4760-B3CA-D5C0C0AF6FD0Q38779978-864F757A-B7C0-467F-97E0-EAF4E3A9DEC5Q39126738-09A0CD91-186F-4B51-983F-7013E4AE4456Q39241718-A742BFA2-E251-4B87-A22F-76550157CB0DQ41472355-596A6EC7-93BE-4178-9800-DE0F496154BAQ42126754-E765975F-5241-42CD-914E-F21582CA0ADEQ42377771-C0DF7D0F-809E-4C55-9820-2959FC1BA814Q44098314-A907FF98-01AB-412E-AFB7-494DF2FF3388Q45758844-7FC68067-FB38-4B67-B5F3-53804B2172DBQ47692369-9B7F8000-63F9-411C-BB8C-E9A995AAB9C0Q47790904-988DEBF7-73A0-4F7F-8A88-0A2A33F2066DQ47907052-A2C5215A-449A-41FA-A0C2-66F010A40D9EQ49330513-1744966E-E1D8-4EE3-924B-E2FAD8178F93Q53046029-53247274-DEE0-4B31-8897-56DA98F02FFAQ53064246-2B07D00E-D84F-4950-BCA6-7C4946829453Q53118004-42346853-08D2-431C-9D59-3C431ABEB97EQ58130542-7DCEA757-E7C8-4EAE-80A8-A56BB36E6267Q58728525-140F8E85-E7C3-4BD8-B49A-18A4323A3945
P2860
High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphoma
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
High-dose methotrexate and rit ...... ed primary B-cell CNS lymphoma
@ast
High-dose methotrexate and rit ...... ed primary B-cell CNS lymphoma
@en
High-dose methotrexate and rit ...... ed primary B-cell CNS lymphoma
@nl
type
label
High-dose methotrexate and rit ...... ed primary B-cell CNS lymphoma
@ast
High-dose methotrexate and rit ...... ed primary B-cell CNS lymphoma
@en
High-dose methotrexate and rit ...... ed primary B-cell CNS lymphoma
@nl
prefLabel
High-dose methotrexate and rit ...... ed primary B-cell CNS lymphoma
@ast
High-dose methotrexate and rit ...... ed primary B-cell CNS lymphoma
@en
High-dose methotrexate and rit ...... ed primary B-cell CNS lymphoma
@nl
P2860
P356
P1433
P1476
High-dose methotrexate and rit ...... ed primary B-cell CNS lymphoma
@en
P2093
Marc C Chamberlain
Sandra K Johnston
P2860
P304
P356
10.1093/NEUONC/NOQ011
P577
2010-02-08T00:00:00Z